A5053120905- Cervical Cancer and HPV Research
- Genital Health and Disease
- Hepatitis B Virus Studies
- Reproductive tract infections research
- Molecular Biology Techniques and Applications
- Global Cancer Incidence and Screening
- DNA and Nucleic Acid Chemistry
- Immunotherapy and Immune Responses
- Endometrial and Cervical Cancer Treatments
- Herpesvirus Infections and Treatments
- Animal Virus Infections Studies
- Colorectal Cancer Screening and Detection
- Virus-based gene therapy research
- T-cell and Retrovirus Studies
- Microbial infections and disease research
- Colorectal and Anal Carcinomas
- Hepatitis Viruses Studies and Epidemiology
- Metal complexes synthesis and properties
- Cancer-related molecular mechanisms research
- DNA Repair Mechanisms
- Carcinogens and Genotoxicity Assessment
- Viral-associated cancers and disorders
- Vaccine Coverage and Hesitancy
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
New Mexico Cancer Center
1999-2025
University of New Mexico
2016-2025
UNM Comprehensive Cancer Center
1996-2025
University of California, San Francisco
2005-2019
National Cancer Institute
1999-2019
Johns Hopkins University
1994-2019
Albert Einstein College of Medicine
2013-2019
National Institutes of Health
2005-2019
University of Virginia Health System
2019
Division of Cancer Epidemiology and Genetics
2005-2019
A phase 3 trial was conducted to evaluate the efficacy of a prophylactic quadrivalent vaccine in preventing anogenital diseases associated with human papillomavirus (HPV) types 6, 11, 16, and 18.In this randomized, placebo-controlled, double-blind involving 5455 women between ages 16 24 years, we assigned 2723 receive 2732 placebo at day 1, month 2, 6. The coprimary composite end points were incidence genital warts, vulvar or vaginal intraepithelial neoplasia, cancer cervical adenocarcinoma...
Approximately 20 percent of adults become infected with human papillomavirus type 16 (HPV-16). Although most infections are benign, some progress to anogenital cancer. A vaccine that reduces the incidence HPV-16 infection may provide important public health benefits.
ABSTRACT Genital human papillomaviruses (HPVs) are commonly detected from clinical samples by consensus PCR methods. Two used primer systems, the MY09-MY11 (MY09/11) primers and GP5+-GP6+ (GP5+/6+) primers, amplify a broad spectrum of HPV genotypes, but with various levels sensitivity among types. Analysis primer-target sequence homology for MY09/11 showed an association between inefficient amplification types number position mismatches, despite accommodation variation inclusion degenerate...
ABSTRACT Amplification of human papillomavirus (HPV) DNA by L1 consensus primer systems (e.g., MY09/11 or GP5 + /6 ) can detect as few 10 to 100 molecules HPV targets from a genital sample. However, genotype determination dot blot hybridization is laborious and requires at least 27 separate hybridizations for substantive HPV-type discrimination. A reverse method was developed which employs biotin-labeled PCR product hybridized an array immobilized oligonucleotide probes. By the strip...
Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated.We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 genotyping performed biopsy samples, histological diagnoses were determined by a pathology panel. Analyses...
The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was investigated in a population that approximates sexually naive women they were "negative to 14 HPV types" mixed HPV-exposed -unexposed (intention-to-treat group).This analysis studied 17 622 aged 15-26 years who enrolled one two randomized, placebo-controlled, efficacy trials for HPV6/11/16/18 (first patient December 28, 2001, studies...
The identification and taxonomy of papillomaviruses has become increasingly complex, as ∼70 human papillomavirus (HPV) types have been described novel HPV genomes continue to be identified. Methods corresponding DNA sequence data bases were designed for the reliable mucosal from clinical specimens. HPVs are identified by amplification a fragment L1 region consensus primer polymerase chain reaction (PCR) subsequent hybridization or restriction length polymorphism analysis. peR fragments may...
In Brief OBJECTIVE: Human papillomavirus (HPV) virus-like particle (VLP) vaccines have demonstrated effectiveness in preventing persistent HPV infections. Whether protection lasts longer than 18 months and, thus, impacts rates of cervical intraepithelial neoplasia (CIN) 2–3 has not yet been established. We present results from an HPV16 L1 VLP vaccine trial through 48 months. METHODS: A total 2,391 women, aged 16–23 years, participated a randomized, double-blind, placebo-controlled trial....
We examined intratype human papillomavirus type 16 (HPV-16) sequence variation in tumor samples that were collected and analyzed an international study of invasive cervical cancer. The collection included tumors from 22 countries five continents. Using our recently developed E6 L1 PCR-based hybridization systems to distinguish HPV-16 variant lineages, we material previously found contain DNA. Of 408 specimens the assay, 376 (92.2%) belonged reported lineages. remaining 32 (7.8%) harbored...
Cervical cancer is caused by persistent infection with human papillomavirus (HPV). Most infections and associated lesions clear spontaneously. It important to define the determinants timing of clearance, so that viral persistence can be recognized managed.We investigated HPV natural history among 4504 subjects from ALTS (Atypical Squamous Cells Undetermined Significance/Low-Grade Intraepithelial Lesions Triage Study). A discrete-time Markov model was used simultaneously describe prevalence,...
Objectives To evaluate the prophylactic efficacy of human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias anogenital warts (condyloma acuminata).
Journal Article A Virus-Like Particle Enzyme-Linked Immunosorbent Assay Detects Serum Antibodies in a Majority of Women Infected With Human Papillomavirus Type 16 Get access Reinhard Kirnbauer, Kirnbauer Search for other works by this author on: Oxford Academic PubMed Google Scholar Nancy L. Hubbert, Hubbert Cosette M. Wheeler, Wheeler Thomas Becker, Becker Douglas R. Lowy, Lowy John T. Schiller JNCI: the National Cancer Institute, Volume 86, Issue 7, 6 April 1994, Pages 494–499,...
In Brief OBJECTIVE: To estimate the fraction of cervical intraepithelial neoplasia 2 (CIN 2) that might regress if untreated using data from Atypical Squamous Cells Undetermined Significance/Low-Grade Intraepithelial Lesions Triage Study (ALTS). METHODS: We compared cumulative occurrence CIN (n=397) and 3 or more severe (n=542) diagnosed by Pathology Quality Control Group in three trial arms—immediate colposcopy, human papillomavirus (HPV) triage, conservative management—over 2-year duration...
Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/16/18-related cervical, vaginal, and vulvar disease through 3 years. We an update on the efficacy of quadrivalent against high-grade lesions based end-of-study data three clinical trials. Additionally, we stratify by several baseline characteristics, including age, smoking status, Papanicolaou (Pap) test results. A total 18,174 females ages 16 26 years were randomized allocated into one trials...